Tianeptine half-life
Small human studies support a short parent-tianeptine half-life near 2.5 hours and a longer-lived principal metabolite.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.
Tianeptine: evidence and interpretation notes
What the representative value means
Small human studies support a short parent-tianeptine half-life near 2.5 hours and a longer-lived principal metabolite. Cirrhosis and age can alter the relationship, so the parent curve is not a treatment or withdrawal guide.
The visual model centers on Tianeptine at 2.5 hours. Nothing in the calculation adjusts for dose history, organ function, interactions, tolerance, or a study’s sampling method.
Tianeptine is an atypical antidepressant entry with direct pharmacokinetic studies in healthy volunteers and risk-factor populations.
The 2.5 hour value produces a short medication curve. Metabolites, liver disease, renal disease, and formulation can change interpretation.
The citations include pharmacokinetic/metabolic parameter research, a cirrhosis/alcoholism pharmacokinetic paper, and the compound record.
This page does not provide treatment, misuse, dependence, or withdrawal guidance.
For Tianeptine, the curve is a narrow pharmacokinetic view. Therapeutic response, misuse risk, metabolites, and discontinuation effects are separate topics.
What each source contributes
- Salmon E et al. Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and risk-factor populations (1988). This metabolism study identifies pathways, metabolites, or analytical targets and does not by itself create a complete human concentration-time curve.
- Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis (1989). This metabolism study identifies pathways, metabolites, or analytical targets and does not by itself create a complete human concentration-time curve.
- PubChem: Tianeptine. This identity record confirms names and compound identity and does not supply a human half-life.
For Tianeptine, the numerical model is tied most closely to Salmon E et al. Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and risk-factor populations (1988). As a metabolism study, it identifies pathways, metabolites, or analytical targets; it does not by itself create a complete human concentration-time curve.
Why there is no range on the chart
This profile plots 2.5 hours for Tianeptine without adding an unsourced high-low band. A single supported center is more honest than manufacturing a range from unrelated routes, populations, or formulations.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 2.5 h as a representative input for Tianeptine. In the simplified model, about 0.1% remains after 24 hours and about 3% remains after five half-lives, or roughly 12.5 h.
This is a short curve. The modeled amount changes noticeably over the same day, while effects, metabolites, and safety questions can still follow a different timeline. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
atypical antidepressant context
Atypical antidepressant entries can differ widely in mechanism, metabolism, and metabolite contribution, so category comparisons should stay pharmacokinetic rather than therapeutic.
- The curve does not predict mood response, adverse effects, or discontinuation symptoms.
- Metabolites and enzyme interactions can change the interpretation of one half-life value.
- Source labels and studies should be checked for formulation and population details.
ComparisonTimeline checkpoints and nearby profiles
Tianeptine timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 6 h | 18.9% | Long-tail portion of the model |
| 12 h | 3.59% | Low modeled remainder, not a clearance guarantee |
| 24 h | 0.13% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Tianeptine within the atypical antidepressant group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
No nearby published profiles are available in this category.
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 2.5 h |
|---|---|
| Curve type | Normalized, first-order decline |
Selection note: Small human studies support a short parent-tianeptine half-life near 2.5 hours and a longer-lived principal metabolite. Cirrhosis and age can alter the relationship, so the parent curve is not a treatment or withdrawal guide.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Research abstract Salmon E et al. Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and risk-factor populations (1988).Metabolism-focused evidence used to identify pathways or analytes. It does not automatically establish a population half-life.
- Research abstract Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis (1989).Metabolism-focused evidence used to identify pathways or analytes. It does not automatically establish a population half-life.
- Identity record PubChem Compound Summary: Tianeptine.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the atypical-antidepressant group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.